Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy

Seminars in Oncology

Volumn 32, Issue SUPPL. 3, 2005, Pages 92-98

  Komaki, Ritsuko ^a   Chang, Joe Y ^a   Wu, Xifeng ^a   Allen, Pamela K ^a   Milas, Luka ^a   Liao, Zhongxing ^a   Fossella, Frank V ^a   Travis, Elizabeth ^a   Spitz, Margaret R ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; BLEOMYCIN; CISPLATIN; ETOPOSIDE; MUTAGENIC AGENT; ANTINEOPLASTIC AGENT; RADIOPROTECTIVE AGENT;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHI SQUARE TEST; CHROMOSOME BREAKAGE; CLINICAL TRIAL; COMPUTER PROGRAM; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DNA REPAIR; DRUG EFFICACY; DRUG SENSITIVITY; DYSGEUSIA; DYSPHAGIA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPOTENSION; KAPLAN MEIER METHOD; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; METAPHASE CHROMOSOME; METASTASIS; MUTAGEN TESTING; NAUSEA AND VOMITING; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; RADIATION PROTECTION; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; SNEEZING; STATISTICAL ANALYSIS; ARTICLE; DNA DAMAGE; GENOMIC INSTABILITY; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIATION DOSE; RADIATION INJURY; RADIATION PNEUMONIA;

ADULT; AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DNA DAMAGE; ESOPHAGITIS; FEMALE; GENOMIC INSTABILITY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTAGENICITY TESTS; RADIATION INJURIES; RADIATION PNEUMONITIS; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY DOSAGE;

EID: 18144383181     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2005.03.016     Document Type: Conference Paper

References (26)

1. W.J. Curran, C.B. Scott, C.J. Langer Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC RTOG 9410 Proc Am Soc Clin Oncol 22 2003 621 (abstr 2499)
2. J.S. Lee, R. Komaki, F.V. Fossella A pilot trial of hyperfractionated thoracic radiation therapy with concurrent cisplatin and oral etoposide for locally advanced inoperable non-small-cell lung cancer A 5-year follow-up report Int J Radiat Oncol Biol Phys 42 1998 479 486
3. J.S. Lee, C. Scott, R. Komaki Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancer Radiation Therapy Oncology Group protocol 91-06 J Clin Oncol 14 1996 1055 1064
4. R. Komaki, C. Scott, D. Ettinger Randomized study of chemotherapy/ radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer Radiation Therapy Oncology Group (RTOG) 9204 Int J Radiat Oncol Biol Phys 38 1997 149 155
5. R. Komaki, C. Scott, J.S. Lee Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC) Comparison of RTOG 83-11 and RTOG 91-06 Am J Clin Oncol 20 1997 435 440
6. D.M. Brizel, T.H. Wasserman, M. Henke Phase III randomized trial of amifostine as a radioprotector in head and neck cancer J Clin Oncol 18 2000 3339 3345
7. G. Kemp, P. Rose, J. Lurain Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities Results of a randomized control trial in patients with advanced ovarian cancer J Clin Oncol 14 1996 2101 2112
8. J.M. Yuhas, J.M. Spellman, F. Culo The role of WR-2721 in radiotherapy and/or chemotherapy Cancer Clin Trials 3 1980 211 216
9. R.L. Capizzi The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine Semin Oncol 26 1999 3 21
10. R. Komaki, J.S. Lee, L. Milas Effects of amifostine on acute toxicity from concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer Report of a randomized comparative trial Int J Radiat Oncol Biol Phys 58 2004 1369 1377
11. M. Berwick, P. Vineis Markers of DNA repair and susceptibility to cancer in humans An epidemiologic review J Natl Cancer Inst 92 2000 874 897
12. X. Wu, S.M. Lippman, J.J. Lee Chromosome instability in lymphocytes A potential indicator of predisposition to oral premalignant lesions Cancer Res 62 2002 2813 2818
13. M. Spitz, S. Lippman, H. Jiang Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract J Natl Cancer Inst 90 1998 243 245
14. Y.-L. Zheng, C.A. Loffredo, Z. Yu Bleomycin-induced chromosome breaks as a risk marker for lung cancer A case-control study with population and hospital controls Carcinogenesis 24 2003 269 274
15. American Joint Committee on Cancer Manual for Cancer Staging 1998 Lippincott Philadelphia, PA
16. D.A. Karnofsky, J.H. Burchenal The clinical evaluation of chemotherapeutic agents in cancer C.M. Macleod Evaluation of Chemotherapeutic Agents 1949 Columbia University Press New York, NY 191 205
17. J.J. Lee, Z. Trizna, T.C. Hsu A statistical analysis of the reliability and classification error in application of the mutagen sensitivity assay Cancer Epidemiol Biomarks Prev 5 1996 191 197
18. J.D. Cox, N. Azarnia, R.W. Byhardt A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with < 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: Report of Radiation Therapy Oncology Group 83-11 J Clin Oncol 8 1990 1543 1555
19. StataCorp Stata Statistical Software Release 7.0 2001 Stata Corporation College Station, TX
20. J.P. Klein, M.L. Moeschberger Survival Analysis Techniques for Censored and Truncated Data 1997 Springer-Verlag New York, NY
21. E.L. Kaplan, P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
22. J. Cuzick A Wilcoxon-type test for trend Stat Med 4 1985 87 90
23. H. Ito, R. Komaki, L. Milas Protection by WR-2721 against radiation plus cisdiamminedichloroplatinum II caused injury to colonic epithelium mice Int J Radiat Oncol Biol Phys 28 1994 899 904
24. D. Antonadou, N. Coliarakis, M. Synodinou Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer Int J Radiat Oncol Biol Phys 51 2001 915 922
25. T. Ishihara, M.D. Sasaki Radiation-induced Chromosome Damage in Man 1983 Alan R. Liss New York, NY
26. E.J. Hall DNA strand breaks and chromosomal aberrations, in Radiobiology for the Radiologist 5th ed 2000 Lippincott Williams & Wilkins Philadelphia, PA 17 32